Individualized Functional Connectivity Targeting in aiTBS for Depression
| 対象疾患 | Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder |
|---|---|
| 相 | 第2相 |
| スポンサー | Brigham and Women's Hospital |
| ステータス | 完了 |
| 参加者数 | 40 名 |
| 介入（薬剤） | transcranial magnetic stimulation |
| 開始日 | 2023年7月15日 |
| 完了日 | 2025年3月17日 |
| 結果公開日 | 2026年7月7日 |
概要
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression. Participants will receive aiTBS treatment, but they will not know if their treatment spot was found with neuroimaging or head measurements.
Montgomery-Åsberg Depression Rating Scale (MADRS)
| Connectivity-based Targeting | 35 Scores on scale |
|---|---|
| Scalp-based Targeting | 31 Scores on scale |
| Connectivity-based Targeting | 6 Scores on scale |
| Scalp-based Targeting | 11 Scores on scale |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital